The BITA Medical Psychedelics, Cannabis, and Ketamine Index is managed by BITA GmbH, an independent Index Provider not affiliated with the Fund or its investment advisor, sub-adviser, or distributor. This rules-based index tracks the performance of companies involved in legal activities related to medical psychedelics, medical cannabis, cannabis pharmaceuticals, CBD derivatives, and ketamine. Constituent companies must meet specific revenue criteria and be listed on a U.S. or Canadian exchange to be included in the index. The index is reconstituted and rebalanced semi-annually and aims to provide exposure to this emerging and evolving sector of healthcare and wellness.
Although the primary focus of the BITA Medical Psychedelics, Cannabis, and Ketamine Index ETF (PSY) may not center around dividends, it reflects the dividend distribution of the underlying index. The distributions typically occur on a periodic basis and are influenced by the dividend policies and performance of the constituent companies. In this case, eligible companies are those deriving a significant portion of their revenue from activities related to medical psychedelics, medical cannabis, cannabis pharmaceuticals, cannabidiol (CBD) derivatives, or ketamine. While the ETF prioritizes tracking the index's total return performance, investors may still expect some dividend returns from these innovative sectors.
Tracking the BITA Medical Psychedelics, Cannabis, and Ketamine Index is the primary objective of the PSY ETF. This index follows a rules-based approach, monitoring a portfolio of companies that operate within the legal framework of their respective countries in the fields of medical psychedelics, medical cannabis, cannabis pharmaceuticals, cannabidiol (CBD) derivatives, and ketamine. Eligible companies for inclusion must derive at least 50% of their revenue from these activities. The ETF aims to provide investors with exposure to the emerging medical psychedelics and cannabis industries while maintaining a diversified portfolio of relevant stocks in these sectors.
The correlation aspect of the BITA Medical Psychedelics, Cannabis, and Ketamine Index (PSY) is essential for investors looking to understand its behavior in relation to the companies involved in medical psychedelics, medical cannabis, cannabis pharmaceuticals, CBD derivatives, and ketamine. This index is designed to track the performance of a portfolio of companies engaged in legal activities related to these sectors. The correlation of the PSY Index with its constituent stocks can provide valuable insights into the broader trends within the medical psychedelics and cannabis industries, helping investors make informed decisions.
PSY ETF is dedicated to tracking the performance of the BITA Medical Psychedelics, Cannabis, and Ketamine Index. This index comprises companies operating within the legal framework of their respective countries, engaged in activities related to medical psychedelics, medical cannabis, cannabis pharmaceuticals, CBD derivatives, and ketamine. The ETF's focus on this unique sector allows investors to participate in the rapidly evolving field of psychedelic medicines and therapeutics, which are being explored for potential treatments of mental illnesses such as depression, addiction, anxiety, and post-traumatic stress disorder. It's important to note that, as of the last update in March 2022, no psychedelic drug product had received marketing approval from the FDA or Health Canada, emphasizing the speculative nature of this sector.
The BITA Medical Psychedelics, Cannabis, and Ketamine Index ETF (PSY) is designed to provide exposure to companies engaged in legal activities related to medical psychedelics, medical cannabis, cannabis pharmaceuticals, cannabidiol (CBD) derivatives, and ketamine. This rules-based index includes common stocks or depositary receipts listed on U.S. or Canadian exchanges, with eligible companies deriving at least 50% of their revenue from these specific sectors. The ETF allows investors to participate in the evolving landscape of psychedelic medicines, cannabis-related therapies, and ketamine-based products, which are being explored for various healthcare treatments and wellness uses.
ETF Insider is a data-driven portfolio analytics and optimization platform that introduces a more efficient and practical way to visualize, analyze and optimize portfolios.
Rather than focusing on the surface-level attributes of ETFs and Mutual Funds, ETF Insider goes deeper by examining the underlying holdings of exchange traded products.
By organizing and structuring that data, investors can easily navigate within their overlapping layers.
This innovative perspective combined with modern data visualization and modeling tools, provides an entirely new approach to portfolio optimization that can quickly expose both portfolio inefficiencies and opportunities.
5 min readDiscover the world of ETFs with a focus on the intriguing PSYK ETF. Unravel the essence of this unique investment vehicle designed to offer exposure to psychedelic medicine and related industries, potentially opening new doors for investors seeking alternative opportunities.
5 min readThe BUFT ETF is a specialized investment fund that focuses on global companies in the relevant sectors. This exchange-traded fund offers investors exposure to a diverse range of innovative and cutting-edge companies engaged in advancements in the industry. Discover the potential growth opportunities and risks associated with investing in this dynamic sector through the BUFT ETF.
5 min readThe PSY ETF is a specialized investment fund that focuses on global companies in the relevant sectors. This exchange-traded fund offers investors exposure to a diverse range of innovative and cutting-edge companies engaged in advancements in the industry. Discover the potential growth opportunities and risks associated with investing in this dynamic sector through the PSY ETF.
ETF Insider is a novel portfolio optimization tool that uses the power of data visualization to gain insight into portfolio compositions, concentration risks, portfolio efficiency and more. Complex financial data can be transformed into visually appealing and easily digestible graphs and charts, allowing investors to quickly identify trends and make well-informed investment decisions. Not only does this save time, but it also increases the accuracy and effectiveness of portfolio management.
